Publications
2024
P111 Immuno-pathological characteristics associated with immune-checkpoint inhibitor colitis
Swaminathan, M., Luchian, A., Ressel, L., Burdak-Rothkamm, S., Sacco, J., Pirmohamed, M., & Mark Pritchard, D. (2024). P111 Immuno-pathological characteristics associated with immune-checkpoint inhibitor colitis. In Poster Presentations (pp. A117-A118). BMJ Publishing Group Ltd and British Society of Gastroenterology. doi:10.1136/gutjnl-2024-bsg.193
Utilizing patient-derived organoids of prostate cancer to predict functional homologous recombination repair deficiency and targeted therapy response
Elsesy, M. E., Oh-Hohenhorst, S. J., Oing, C., Eckhardt, A., Burdak-Rothkamm, S., Alawi, M., . . . Mansour, W. Y. (2024). Utilizing patient-derived organoids of prostate cancer to predict functional homologous recombination repair deficiency and targeted therapy response. European Urology, 85, S2217. doi:10.1016/s0302-2838(24)01655-5
2023
PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research
Jones, R. P., Mielgo, A., Schmid, M., Bury, D., Andrews, T., Burdak-Rothkamm, S., . . . Vimalachandran, D. (2023). PINCER (A Platform Study for solId orgaN CancERs): an agile pan-network platform study to deliver high-quality translational research. BRITISH JOURNAL OF SURGERY. doi:10.1093/bjs/znad097
Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease
Elsesy, M. E., Oh-Hohenhorst, S. J., Oing, C., Eckhardt, A., Burdak-Rothkamm, S., Alawi, M., . . . Mansour, W. Y. (2023). Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease. MOLECULAR ONCOLOGY, 17(6), 1129-1147. doi:10.1002/1878-0261.13382
2022
Monitoring Very Low Dose Radiation Damage in DNA Using "Field-Friendly" Biomarkers
Rothkamm, K., & Burdak-Rothkamm, S. (2022). Monitoring Very Low Dose Radiation Damage in DNA Using "Field-Friendly" Biomarkers. In Unknown Book (pp. 137-151). doi:10.1007/978-94-024-2101-9_9
2021
Mutational Signature Analysis for Detection of DNA Damage Repair Deficiency in Prostate Cancer
Burdak-Rothkamm, S., Alawi, M., Droste, C., Petersen, C., & Rothkamm, K. (2021). Mutational Signature Analysis for Detection of DNA Damage Repair Deficiency in Prostate Cancer. In JOURNAL OF PATHOLOGY Vol. 255 (pp. S46). Retrieved from https://www.webofscience.com/
DNA Damage Repair Deficiency and Synthetic Lethality for Cancer Treatment
Burdak-Rothkamm, S., & Rothkamm, K. (2021). DNA Damage Repair Deficiency and Synthetic Lethality for Cancer Treatment. TRENDS IN MOLECULAR MEDICINE, 27(1), 91-92. doi:10.1016/j.molmed.2020.09.011
Interplay between DNA replication stress, chromatin dynamics and DNA-damage response for the maintenance of genome stability
Mognato, M., Burdak-Rothkamm, S., & Rothkamm, K. (2021). Interplay between DNA replication stress, chromatin dynamics and DNA-damage response for the maintenance of genome stability. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 787. doi:10.1016/j.mrrev.2020.108346
2020
Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays
Rothkamm, K., Christiansen, S., Rieckmann, T., Horn, M., Frenzel, T., Brinker, A., . . . Burdak-Rothkamm, S. (2020). Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays. CANCER LETTERS, 493, 179-188. doi:10.1016/j.canlet.2020.08.038
DNA Damage Repair Deficiency in Prostate Cancer
Burdak-Rothkamm, S., Mansour, W. Y., & Rothkamm, K. (2020). DNA Damage Repair Deficiency in Prostate Cancer. TRENDS IN CANCER, 6(11), 974-984. doi:10.1016/j.trecan.2020.05.011
Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
Elsesy, M. E., Oh-Hohenhorst, S. J., Loeser, A., Oing, C., Mutiara, S., Koecher, S., . . . Mansour, W. Y. (2020). Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair. CANCERS, 12(9). doi:10.3390/cancers12092467
2019
A functional <i>ex vivo</i> assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer
Koecher, S., Beyer, B., Lange, T., Nordquist, L., Volquardsen, J., Burdak-Rothkamm, S., . . . Mansour, W. Y. (2019). A functional <i>ex vivo</i> assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer. INTERNATIONAL JOURNAL OF CANCER, 144(7), 1685-1696. doi:10.1002/ijc.32018
Prolonged trifluridine/tipiracil treatment radiosensitises colorectal cancer cells
Rothkamm, K., Rieckmann, T., Christiansen, S., Brinker, A., Stein, A., Schumacher, U., . . . Burdak-Rothkamm, S. (2019). Prolonged trifluridine/tipiracil treatment radiosensitises colorectal cancer cells. RADIOTHERAPY AND ONCOLOGY, 133, S602-S603. doi:10.1016/S0167-8140(19)31505-1
Targeting TEMPRSS2: ERG fusion to achieve a tumor-specific radiosensitization in prostate cancer
Koecher, S., Beyer, B., Lange, T., Nordquist, L., Burdak-Rothkamm, S., Schlomm, T., . . . Mansour, W. (2019). Targeting TEMPRSS2: ERG fusion to achieve a tumor-specific radiosensitization in prostate cancer. RADIOTHERAPY AND ONCOLOGY, 133, S338-S339. doi:10.1016/S0167-8140(19)31055-2
Radiosensitization of Colorectal Cancer Cells by sustained Treatment with Trifluridine/Tipiracil
Rothkamm, K., Rieckmann, T., Christiansen, S., Brinker, A., Stein, A., Schumacher, U., . . . Burdak-Rothkamm, S. (2019). Radiosensitization of Colorectal Cancer Cells by sustained Treatment with Trifluridine/Tipiracil. In STRAHLENTHERAPIE UND ONKOLOGIE Vol. 195 (pp. S71). Retrieved from https://www.webofscience.com/
2018
Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome
Grupp, K., Hofmann, B., Kutup, A., Bachmann, K., Bogoevski, D., Melling, N., . . . Wilczak, W. (2018). Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome. BMC CANCER, 18. doi:10.1186/s12885-018-5032-z
Radiation-induced bystander and systemic effects serve as a unifying model system for genotoxic stress responses
Burdak-Rothkamm, S. V., & Rothkamm, K. (2018). Radiation-induced bystander and systemic effects serve as a unifying model system for genotoxic stress responses. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 778, 13-22. doi:10.1016/j.mrrev.2018.08.001
Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Benten, D., Behrang, Y., Unrau, L., Weissmann, V., Wolters-Eisfeld, G., Burdak-Rothkamm, S., . . . Schrader, J. (2018). Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. MOLECULAR CANCER RESEARCH, 16(3), 496-507. doi:10.1158/1541-7786.MCR-17-0163
2017
High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer
Burdelski, C., Shihada, R., Hinsch, A., Angerer, A., Goebel, C., Friedrich, E., . . . Jacobsen, F. (2017). High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. PROSTATE, 77(15), 1528-1538. doi:10.1002/pros.23431
Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.
Person, F., Wilczak, W., Hube-Magg, C., Burdelski, C., Möller-Koop, C., Simon, R., . . . Jacobsen, F. (2017). Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 39(10), 1010428317712166. doi:10.1177/1010428317712166
Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
Jacobsen, F., Taskin, B., Melling, N., Sauer, C., Wittmer, C., Hube-Magg, C., . . . Burdak-Rothkamm, S. (2017). Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. BMC CANCER, 17. doi:10.1186/s12885-017-3489-9
Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation
Schrader, J., Henes, F. O., Perez, D., Burdak-Rothkamm, S., Stein, A., Izbicki, J. R., & Lohse, A. W. (2017). Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation. ANNALS OF ONCOLOGY, 28(4), 904-905. doi:10.1093/annonc/mdx007
2016
Targeted nanoparticles for tumour radiotherapy enhancement-the long dawn of a golden era?
Gargioni, E., Schulz, F., Raabe, A., Burdak-Rothkamm, S., Rieckmann, T., & Rothkamm, K. (2016). Targeted nanoparticles for tumour radiotherapy enhancement-the long dawn of a golden era?. ANNALS OF TRANSLATIONAL MEDICINE, 4(24). doi:10.21037/atm.2016.12.46
2015
<i>FGFR1</i> Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma
von Loga, K., Kohlhaussen, J., Burkhardt, L., Simon, R., Steurer, S., Burdak-Rothkamm, S., . . . Krech, T. (2015). <i>FGFR1</i> Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma. PLOS ONE, 10(11). doi:10.1371/journal.pone.0141867
DNA damage foci: Meaning and significance
Rothkamm, K., Barnard, S., Moquet, J., Ellender, M., Rana, Z., & Burdak-Rothkamm, S. (2015). DNA damage foci: Meaning and significance. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 56(6), 491-504. doi:10.1002/em.21944
Radioprotection of targeted and bystander cells by methylproamine
Burdak-Rothkamm, S., Smith, A., Lobachevsky, P., Martin, R., & Prise, K. M. (2015). Radioprotection of targeted and bystander cells by methylproamine. STRAHLENTHERAPIE UND ONKOLOGIE, 191(3), 248-255. doi:10.1007/s00066-014-0751-9
BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells
Burdak-Rothkamm, S., Rothkamm, K., McClelland, K., Al Rashid, S. T., & Prise, K. M. (2015). BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells. CANCER LETTERS, 356(2), 454-461. doi:10.1016/j.canlet.2014.09.043
2011
Contribution of the BRCA/FA Pathway to the Radiation-induced DNA Damage Response in Non-targeted Cells
Burdak-Rothkamm, S., Rothkamm, K., & Prise, K. M. (2011). Contribution of the BRCA/FA Pathway to the Radiation-induced DNA Damage Response in Non-targeted Cells. In JOURNAL OF PATHOLOGY Vol. 224 (pp. S12). Retrieved from https://www.webofscience.com/
Ionizing Radiation-Induced DNA Strand Breaks and γ-H2AX Foci in Cells Exposed to Nitric Oxide
Rothkamm, K., & Burdak-Rothkamm, S. (2011). Ionizing Radiation-Induced DNA Strand Breaks and γ-H2AX Foci in Cells Exposed to Nitric Oxide. In NITRIC OXIDE: METHODS AND PROTOCOLS (Vol. 704, pp. 17-25). doi:10.1007/978-1-61737-964-2_2
2010
Cohesin promotes the repair of ionizing radiation-induced DNA double-strand breaks in replicated chromatin
Bauerschmidt, C., Arrichiello, C., Burdak-Rothkamm, S., Woodcock, M., Hill, M. A., Stevens, D. L., & Rothkamm, K. (2010). Cohesin promotes the repair of ionizing radiation-induced DNA double-strand breaks in replicated chromatin. NUCLEIC ACIDS RESEARCH, 38(2), 477-487. doi:10.1093/nar/gkp976
Inter-Cellular Activation of DNA Damage Signalling Following Radiation Treatment
Burdak-Rothkamm, S., Rothkamm, K., & Prise, K. (2010). Inter-Cellular Activation of DNA Damage Signalling Following Radiation Treatment. In JOURNAL OF PATHOLOGY Vol. 222 (pp. S11). Retrieved from https://www.webofscience.com/
2009
New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells
Burdak-Rothkamm, S., & Prise, K. M. (2009). New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells. EUROPEAN JOURNAL OF PHARMACOLOGY, 625(1-3), 151-155. doi:10.1016/j.ejphar.2009.09.068
DNA and chromosomal damage in response to intermittent extremely low-frequency magnetic fields
Burdak-Rothkamm, S., Rothkamm, K., Folkard, M., Patel, G., Hone, P., Lloyd, D., . . . Prise, K. M. (2009). DNA and chromosomal damage in response to intermittent extremely low-frequency magnetic fields. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 672(2), 82-89. doi:10.1016/j.mrgentox.2008.10.016
The DNA Damage Response in Nontargeted Cells
Prise, K. M., Schettino, G., & Burdak-Rothkamm, S. (2009). The DNA Damage Response in Nontargeted Cells. In Unknown Book (pp. 193-198). doi:10.1007/978-4-431-88659-4_24
2008
Oral Polio vaccination leads to oligoclonal expansion of TCRBV16+and TCRBV13+T cells in the colon of rhesus macaques
Hoerer, S., Burdak-Rothkamm, S., Allers, K., Schneider, T., & Duchmann, R. (2008). Oral Polio vaccination leads to oligoclonal expansion of TCRBV16+and TCRBV13+T cells in the colon of rhesus macaques. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 85(3), 189-195. doi:10.1016/j.yexmp.2008.08.001
ATM acts downstream of ATR in the DNA damage response signaling of bystander cells
Burdak-Rothkamm, S., Rothkamm, K., & Prise, K. M. (2008). ATM acts downstream of ATR in the DNA damage response signaling of bystander cells. CANCER RESEARCH, 68(17), 7059-7065. doi:10.1158/0008-5472.CAN-08-0545
ATR-dependent bystander effects in nontargeted cells
Rothkamm, S. B., Rothkamm, K., & Prise, K. M. (2008). ATR-dependent bystander effects in nontargeted cells. International Journal of Low Radiation, 5(1), 22. doi:10.1504/ijlr.2008.018814
2007
Cytoplasmic irradiation induces mitochondrial-dependent 53BP1 protein relocalization in irradiated and bystander cells
Tartier, L., Gilchrist, S., Burdak-Rothkamm, S., Folkard, M., & Prise, K. M. (2007). Cytoplasmic irradiation induces mitochondrial-dependent 53BP1 protein relocalization in irradiated and bystander cells. CANCER RESEARCH, 67(12), 5872-5879. doi:10.1158/0008-5472.CAN-07-0188
ATR-dependent radiation-induced γH2AX foci in bystander primary human astrocytes and glioma cells
Burdak-Rothkamm, S., Short, S. C., Folkard, M., Rothkamm, K., & Prise, K. M. (2007). ATR-dependent radiation-induced γH2AX foci in bystander primary human astrocytes and glioma cells. ONCOGENE, 26(7), 993-1002. doi:10.1038/sj.onc.1209863
New insights on radiation-induced bystander signalling and its relationship to DNA repair
Prise, K. M., Burdak-Rothkamm, S., Folkard, M., Kashino, G., Shao, C., & Tartier, L. (2007). New insights on radiation-induced bystander signalling and its relationship to DNA repair. International Congress Series, 1299, 121-127. doi:10.1016/j.ics.2006.10.018
2005
Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa®)
Burdak-Rothkamm, S., Rübe, C. E., Nguyen, T. P., Ludwig, D., Feldmann, K., Wiegel, T., & Rübe, C. (2005). Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa®). STRAHLENTHERAPIE UND ONKOLOGIE, 181(3), 197-204. doi:10.1007/s00066-005-1319-5
2004
The relevance of cytokines in the radiation-induced lung reaction.: Experimental basis and clinical significance
Rübe, C. E., Rodemann, H. P., & Rübe, C. (2004). The relevance of cytokines in the radiation-induced lung reaction.: Experimental basis and clinical significance. STRAHLENTHERAPIE UND ONKOLOGIE, 180(9), 541-549. doi:10.1007/s00066-004-1279-1
Combination of the EGFR-tyrosine kinase inhibitor ZD1839 (gefitinib, Iressa) and ionizing irradiation in glioma cell lines
Burdak-Rothkamm, S., Nguyen, T. P., Rau, N., Justinger, C., Rübe, C. E., & Rübe, C. (2004). Combination of the EGFR-tyrosine kinase inhibitor ZD1839 (gefitinib, Iressa) and ionizing irradiation in glioma cell lines. In RADIOTHERAPY AND ONCOLOGY Vol. 73 (pp. S370-S371). Retrieved from https://www.webofscience.com/
2003
484 Biological markers associated with sensitivity of tumour cells to the epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 and ionizing radiation
Burdak-Rothkamm, S., Ruebe, C. E., Nguyen, T. P., Ludwig, D., Feldmann, K., Wiegel, T., & Ruebe, C. (2003). 484 Biological markers associated with sensitivity of tumour cells to the epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 and ionizing radiation. European Journal of Cancer Supplements, 1(5), S147. doi:10.1016/s1359-6349(03)90516-7